Infection control in cystic fibrosis: Practical recommendations for the hospital, clinic, and social settings

American Journal of Infection Control

Volumn 28, Issue 5, 2000, Pages 381-385

  Saiman, Lisa ^a   MacDonald, Noni ^b   Burns, Jane L ^c   Hoiby, Niels ^d,e   Speert, David P ^f   Weber, David ^g  

^a Howard Hughes Medical Institute   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME;

BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIUM CULTURE; BURKHOLDERIA CEPACIA; CROSS INFECTION; CYSTIC FIBROSIS; DISEASE TRANSMISSION; DISINFECTION; EPIDEMIC; HEALTH CARE POLICY; HOSPITAL; HUMAN; INFECTION CONTROL; NEWBORN SCREENING; PHYSIOTHERAPY; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; SANITATION; VACCINATION;

EID: 0033791509     PISSN: 01966553     EISSN: None     Source Type: Journal    
DOI: 10.1067/mic.2000.106337     Document Type: Article

References (43)

1. Does centralized treatment of cystic fibrosis patients increase the risk of Pseudomonas aeruginosa infection
2. Estimated risk of cross-infection with Pseudomonas aeruginosa in Danish cystic fibrosis patients
3. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995)
4. Pseudomonas aeruginosa and Burkholderia cepacia infection in cystic fibrosis patients treated in Toronto and Copenhagen
5. Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in a cystic fibrosis clinic
6. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre
7. Comparison of genome finger-printing with conventional typing methods used on Pseudomonas aeruginosa isolates from cystic fibrosis patients
8. Spread of β-lactam resistant Pseudomonas aeruginosa in a cystic fibrosis clinic
9. Genome fingerprinting as a typing method used on polyagglutinable Pseudomonas aeruginosa isolates from cystic fibrosis patients
10. Acquisition of Pseudomonas aeruginosa in children with cystic fibrosis
11. Communicability of Pseudomonas aeruginosa in a cystic fibrosis summer camp
12. Hospital epidemiology of Pseudomonas aeruginosa from patients with cystic fibrosis
13. Random amplified polymorphic DNA typing of Pseudomonas aeruginosa from patients with cystic fibrosis
14. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis
15. Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis
16. Pseudomonas cepacia at summer camps for persons with cystic fibrosis
17. Possible nosocomial transmission of Pseudomonas cepacia in patients with cystic fibrosis
18. Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward
19. Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak
20. An epidemic of Burkholderia cepacia transmitted between patients with and without cystic fibrosis
21. The epidemiology of epidemic Pseudomonas cepacia
22. Nosocomial Burkholderia cepacia outbreaks and pseudo-outbreaks
23. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis
24. Is Burkholderia (Pseudomonas) cepacia disseminated from cystic fibrosis patients during physiotherapy?
25. Identification of Burkholderia cepacia isolated from patients with cystic fibrosis and use of a simple new selective procedure
26. Burkholderia cepacia. Management issues and new insights
27. An outbreak of Burkholderia cepacia lower respiratory tract infection associated with contaminated albuterol nebulizing solution
28. Transmissibility and infection control implications of Burkholderia cepacia in cystic fibrosis
29. Molecular epidemiology of Burkholderia cepacia in two Australian cystic fibrosis centers
30. Hand-washing patterns in medical intensive care units
31. Analysis of restriction fragment length polymorphism and ribotyping of multiresistant Stenotrophomonas maltophilia isolated from persisting lung infection in a cystic fibrosis patient
32. Molecular epidemiology of Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans in cystic fibrosis center
33. Epidemiological typing of Stenotrophomonas (Xanthomonas) maltophilia by PCR
34. Recovery of Pseudomonas cepacia and other Pseudomonas species from the environment
35. Guideline for prevention of nosocomial pneumonia
36. Typing of Staphylococcus aureus by pulsed-field gel electrophoresis, zymotyping, capsular typing, and phage typing: Resolution of clonal relationships
37. Persistence of Staphylococcus aureus strains among cystic fibrosis patients over extended periods of time
38. Nosocomial infections associated with respiratory therapy
39. Environmental issues and nosocomial infections
40. Water as a reservoir of nosocomial pathogens
41. APIC guidelines for selection and use of disinfectants
42. Low bacterial contamination of nebulizers in home treatment of cystic fibrosis patients
43. Susceptibility of antibiotic-susceptible and antibiotic resistant hospital bacteria to disinfectants